[go: up one dir, main page]

PL2201012T3 - Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b - Google Patents

Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b

Info

Publication number
PL2201012T3
PL2201012T3 PL08806741T PL08806741T PL2201012T3 PL 2201012 T3 PL2201012 T3 PL 2201012T3 PL 08806741 T PL08806741 T PL 08806741T PL 08806741 T PL08806741 T PL 08806741T PL 2201012 T3 PL2201012 T3 PL 2201012T3
Authority
PL
Poland
Prior art keywords
pyrrolo
inhibitors
protein kinase
pyrimidin derivatives
pyrimidin
Prior art date
Application number
PL08806741T
Other languages
English (en)
Inventor
Paul David Johnson
Andrew Leach
Richard William Arthur Luke
Zbigniew Stanley Matusiak
Jeffrey James Morris
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40251789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2201012(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL2201012T3 publication Critical patent/PL2201012T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL08806741T 2007-10-11 2008-10-09 Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b PL2201012T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97919207P 2007-10-11 2007-10-11
US4786208P 2008-04-25 2008-04-25
EP08806741.8A EP2201012B1 (en) 2007-10-11 2008-10-09 Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors
PCT/GB2008/050925 WO2009047563A1 (en) 2007-10-11 2008-10-09 Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors

Publications (1)

Publication Number Publication Date
PL2201012T3 true PL2201012T3 (pl) 2014-11-28

Family

ID=40251789

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08806741T PL2201012T3 (pl) 2007-10-11 2008-10-09 Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b

Country Status (43)

Country Link
US (8) US8101623B2 (pl)
EP (1) EP2201012B1 (pl)
JP (2) JP4705695B2 (pl)
KR (1) KR101494734B1 (pl)
CN (1) CN101861321B (pl)
AR (1) AR068846A1 (pl)
AU (1) AU2008309383B2 (pl)
BR (1) BRPI0818533B8 (pl)
CA (1) CA2701057C (pl)
CL (1) CL2008003023A1 (pl)
CO (1) CO6270328A2 (pl)
CR (1) CR11359A (pl)
CU (1) CU23886B1 (pl)
CY (1) CY1116929T1 (pl)
DK (1) DK2201012T3 (pl)
DO (1) DOP2010000103A (pl)
EA (1) EA018512B1 (pl)
ES (1) ES2522365T3 (pl)
FI (1) FIC20240039I1 (pl)
FR (1) FR24C1046I1 (pl)
GT (1) GT201000082A (pl)
HK (1) HK1143154A1 (pl)
HN (1) HN2010000653A (pl)
HR (1) HRP20140807T1 (pl)
HU (1) HUS2400038I1 (pl)
IL (1) IL204721A (pl)
ME (1) ME01999B (pl)
MX (1) MX2010003927A (pl)
MY (1) MY150059A (pl)
NI (1) NI201000050A (pl)
NL (1) NL301299I2 (pl)
NO (1) NO2024050I1 (pl)
NZ (1) NZ585261A (pl)
PE (2) PE20130152A1 (pl)
PL (1) PL2201012T3 (pl)
PT (1) PT2201012E (pl)
RS (1) RS53552B1 (pl)
SA (1) SA08290625B1 (pl)
SI (1) SI2201012T1 (pl)
TW (1) TWI453021B (pl)
UY (1) UY31384A1 (pl)
WO (1) WO2009047563A1 (pl)
ZA (1) ZA201002318B (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
DK3421471T3 (da) 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
JP5339291B2 (ja) 2006-08-10 2013-11-13 オンコセラピー・サイエンス株式会社 乳癌に関連する遺伝子およびポリペプチド
TWI453021B (zh) 2007-10-11 2014-09-21 Astrazeneca Ab 新穎蛋白質激酶ｂ抑制劑
WO2011002772A1 (en) * 2009-06-29 2011-01-06 Oncotherapy Science, Inc. Imidazopyridine derivatives and pbk inhibitors containing the same
GB201020161D0 (en) 2010-11-26 2011-01-12 Almac Discovery Ltd Pharmaceutical compounds
ES2617339T3 (es) 2010-12-16 2017-06-16 Calchan Limited Derivados de pirrolopirimidina inhibidores de ASK1
BR112013017722A2 (pt) 2011-01-11 2016-07-12 Glaxosmithkline Llc combinação
MX357447B (es) * 2011-04-01 2018-07-10 Astrazeneca Ab Tratamiento terapeutico.
LT2785349T (lt) 2011-11-30 2019-12-10 Astrazeneca Ab Kombinuotas vėžio gydymas
AU2013204533B2 (en) * 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
MA38287B1 (fr) 2013-01-23 2018-08-31 Astrazeneca Ab Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
JP6295578B2 (ja) * 2013-09-30 2018-03-20 凸版印刷株式会社 反応容器、核酸解析装置、および核酸解析方法
EP4265300A3 (en) * 2013-10-01 2023-11-29 Novartis AG Combination
PL3105218T3 (pl) 2014-02-13 2020-03-31 Incyte Corporation Cyklopropyloaminy jako inhibitory lsd1
SMT201900620T1 (it) 2014-02-13 2020-01-14 Incyte Corp Ciclopropilammine come inibitori di lsd1
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
CA2948444C (en) * 2014-05-28 2022-07-26 Astrazeneca Ab Processes for the preparation of azd5363 and intermediate used therein
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
ES2757948T3 (es) 2015-04-03 2020-04-30 Incyte Corp Compuestos heterocíclicos como inhibidores LSD1
AU2016306555B2 (en) * 2015-08-12 2021-01-28 Incyte Holdings Corporation Salts of an LSD1 inhibitor
TW201726140A (zh) * 2015-09-17 2017-08-01 瑞典商阿斯特捷利康公司 治療癌症之新型生物標記及方法
IL262488B (en) 2016-04-22 2022-08-01 Incyte Corp lsdi inhibitor formulations
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
EP4021450A1 (en) 2019-08-26 2022-07-06 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
EP4054582A1 (en) 2019-11-04 2022-09-14 Astrazeneca AB Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
WO2022147519A1 (en) * 2021-01-04 2022-07-07 Teva Pharmaceuticals International Gmbh Solid state forms of capivasertib and process for preparation thereof
AU2023246862A1 (en) 2022-03-31 2024-10-31 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
CN114601836B (zh) * 2022-04-12 2022-12-06 四川大学华西医院 一种akt抑制剂在制备治疗乳腺癌的药物中的应用
TW202430176A (zh) 2022-10-17 2024-08-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
WO2024104561A1 (en) 2022-11-15 2024-05-23 Astrazeneca Ab Therapeutic combinations of capivasertib and venetoclax
WO2024245953A1 (en) 2023-05-26 2024-12-05 Astrazeneca Ab Pharmaceutical compositions
TW202448458A (zh) 2023-06-02 2024-12-16 美商亞文納營運公司 雌激素受體降解劑與ａｋｔ抑制劑之組合

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637271A (pl) 1963-04-04 1900-01-01
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
AU719434B2 (en) 1996-02-13 2000-05-11 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
EP0944388A4 (en) 1996-04-03 2001-08-16 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
WO1998035985A1 (en) 1997-02-12 1998-08-20 The Regents Of The University Of Michigan Protein markers for lung cancer and use thereof
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ID24300A (id) 1997-08-05 2000-07-13 Pfizer Prod Inc 4-AMINOPIROL(3,2-d)PIRIMIDIN SEBAGAI ANTAGONIS-ANTAGONIS RESEPTOR NEUROPEPTIDA Y
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
IL139811A0 (en) 1998-06-04 2002-02-10 Abbott Lab Cell adhesion-inhibiting antinflammatory compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
SI1154774T1 (en) 1999-02-10 2005-10-31 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
PL203782B1 (pl) 1999-11-05 2009-11-30 Astrazeneca Ab Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
US7160890B2 (en) * 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
DK1255752T3 (da) 2000-02-15 2007-11-26 Sugen Inc Pyrrolsubstituerede 2-indolinonproteinkinaseinhibitorer
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
EE200200711A (et) 2000-06-26 2004-06-15 Pfizer Products Inc. Pürrolo[2,3-d]pürimidiinühendid kui immunosupressiivsed vahendid
KR20030022264A (ko) 2000-07-07 2003-03-15 앤지오젠 파마슈티칼스 리미티드 신생 혈관 형성 억제제인 콜치놀 유도체
CA2411160A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
AU9378801A (en) 2000-08-31 2002-03-13 Hoffmann La Roche Quinazoline derivatives as alpha-1 adrenergic antagonists
US6680324B2 (en) * 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
CN1263757C (zh) 2000-12-01 2006-07-12 Osi制药公司 特异于腺苷a1,a2a和a3受体的化合物及其应用
US6673802B2 (en) * 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6962936B2 (en) * 2001-04-27 2005-11-08 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
CN100503608C (zh) 2002-01-07 2009-06-24 卫材R&D管理株式会社 脱氮嘌呤及其用途
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
JPWO2004002531A1 (ja) * 2002-06-26 2005-10-27 小野薬品工業株式会社 血管の収縮または拡張による疾患治療剤
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US20050288503A1 (en) 2002-09-06 2005-12-29 Adams Jerry L Novel compounds
CA2505529C (en) 2002-11-08 2013-12-24 President And Fellows Of Harvard College Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors
EP1568699A4 (en) * 2002-12-04 2007-08-15 Eisai R&D Man Co Ltd 1,3-DIHYDROIMIDAZOLE CONNECTION WITH CONDENSED RING
EP1444982A1 (de) 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
JP2006519846A (ja) 2003-03-10 2006-08-31 シェーリング　コーポレイション 複素環式キナーゼインヒビター：使用および合成の方法
US20060128956A1 (en) 2003-04-21 2006-06-15 Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky (Purin-6-yl) amino acid and production method thereof
FR2856685B1 (fr) 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
EP1663204B1 (en) 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
CN102786482A (zh) 2003-11-21 2012-11-21 阿雷生物药品公司 Akt蛋白激酶抑制剂
US7511159B2 (en) * 2003-12-25 2009-03-31 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
WO2005095386A1 (en) * 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
AU2005249380C1 (en) * 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
US7994172B2 (en) * 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
FR2880540B1 (fr) 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
FR2880626B1 (fr) 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
WO2006091450A1 (en) 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
WO2007007919A2 (en) 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
TW200738709A (en) 2006-01-19 2007-10-16 Osi Pharm Inc Fused heterobicyclic kinase inhibitors
EP2029592A1 (en) 2006-04-25 2009-03-04 Astex Therapeutics Limited Pharmaceutical compounds
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
DK3421471T3 (da) 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
US20090253718A1 (en) 2006-04-25 2009-10-08 Astex Therapeutics Limited Pharmaceutical Compounds
US20090124610A1 (en) 2006-04-25 2009-05-14 Gordon Saxty Pharmaceutical compounds
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
KR20090091350A (ko) 2006-12-21 2009-08-27 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로 유용한 ５-시아노-４-피롤로[２,３ｂ]피리딘-３-일)-피리디민 유도체
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
TWI453021B (zh) 2007-10-11 2014-09-21 Astrazeneca Ab 新穎蛋白質激酶ｂ抑制劑

Also Published As

Publication number Publication date
US20200239483A1 (en) 2020-07-30
KR101494734B1 (ko) 2015-02-26
BRPI0818533A2 (pt) 2017-06-06
KR20100101077A (ko) 2010-09-16
EA018512B1 (ru) 2013-08-30
JP5330430B2 (ja) 2013-10-30
BRPI0818533B1 (pt) 2020-12-01
NZ585261A (en) 2011-10-28
US20220220116A1 (en) 2022-07-14
MX2010003927A (es) 2010-04-30
US11236095B2 (en) 2022-02-01
US11760760B2 (en) 2023-09-19
TWI453021B (zh) 2014-09-21
US8101623B2 (en) 2012-01-24
CY1116929T1 (el) 2017-04-05
PE20090964A1 (es) 2009-08-15
NL301299I2 (nl) 2024-12-11
ZA201002318B (en) 2012-09-26
HN2010000653A (es) 2013-03-18
US20180312516A1 (en) 2018-11-01
US10654855B2 (en) 2020-05-19
GT201000082A (es) 2015-03-10
US20170057969A1 (en) 2017-03-02
CA2701057A1 (en) 2009-04-16
US20120190679A1 (en) 2012-07-26
BRPI0818533B8 (pt) 2021-05-25
US10059714B2 (en) 2018-08-28
IL204721A (en) 2013-10-31
EP2201012A1 (en) 2010-06-30
AU2008309383A1 (en) 2009-04-16
US20240109902A1 (en) 2024-04-04
AR068846A1 (es) 2009-12-09
TW200927128A (en) 2009-07-01
SI2201012T1 (sl) 2014-10-30
US20150182531A1 (en) 2015-07-02
SA08290625B1 (ar) 2012-02-12
CU23886B1 (es) 2013-04-19
US12252495B2 (en) 2025-03-18
CN101861321B (zh) 2013-02-06
FIC20240039I1 (fi) 2024-11-12
CL2008003023A1 (es) 2009-11-27
NI201000050A (es) 2011-12-22
RS53552B1 (en) 2015-02-27
CR11359A (es) 2010-07-15
ES2522365T3 (es) 2014-11-14
CN101861321A (zh) 2010-10-13
EA201000552A1 (ru) 2010-12-30
NO2024050I1 (no) 2024-11-18
JP4705695B2 (ja) 2011-06-22
DOP2010000103A (es) 2010-05-31
CO6270328A2 (es) 2011-04-20
CA2701057C (en) 2015-03-24
UY31384A1 (es) 2009-05-29
FR24C1046I1 (fr) 2025-01-10
US9492453B2 (en) 2016-11-15
DK2201012T3 (da) 2014-09-08
IL204721A0 (en) 2010-11-30
HK1143154A1 (en) 2010-12-24
CU20100062A7 (es) 2011-10-05
HRP20140807T1 (hr) 2014-11-21
PE20130152A1 (es) 2013-03-17
ME01999B (me) 2015-05-20
MY150059A (en) 2013-11-29
AU2008309383B2 (en) 2012-04-19
EP2201012B1 (en) 2014-06-25
JP2011157364A (ja) 2011-08-18
WO2009047563A1 (en) 2009-04-16
HUS2400038I1 (hu) 2024-12-28
PT2201012E (pt) 2014-09-04
US20090163524A1 (en) 2009-06-25
JP2011500547A (ja) 2011-01-06

Similar Documents

Publication Publication Date Title
HUS2400038I1 (hu) Pirrolo[2,3-d]primidin származékok, mint protein kináz B inhibitorok
IL278119B (en) Disubstituted pyrazolo[5.1–a]pyrimidine compounds as trk kinase inhibitors
HRP20181912T1 (hr) Derivati pirolo[2,3-d]pirimidina kao inhibitori janus kinaze
SI1893612T1 (sl) Pirolo b piridin derivati kot protein kinazni inhibitorji
ZA201200982B (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
ZA201101701B (en) Pyrrolo[2,3-d]pyrimidine compounds
ZA200809796B (en) Pyrazolo [1,5-A]pyrimidines as CDK inhibitors
ZA201004368B (en) Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors
ZA200803173B (en) Pyrazolo [4,3-d] Pyrimidin-5-yl) Derivative used as PDE5 Inhibitors